TORONTO, June 5 /CNW/ - NOVX Systems Inc. has received clearance from the
U.S. Food and Drug Administration to market iMDx(TM) System (iMDx) for
point-of-care screening for drugs of abuse. "This marks a major milestone for
NOVX as it paves the way for product rollout to many thousands of addiction
and pain treatment providers as well as employers requiring on-site screening
for substance abuse. The iMDx System is unique in its level of automation and
ease of use. It enables care providers and testing centers to obtain accurate
and timely results at the point-of-care." said Dr. Tino Alavie, President and
CEO of NOVX Systems. "With this approval, NOVX can now provide a comprehensive
solution previously unavailable from a single source."
On-Site Screening Redefined
NOVX provides a simple yet powerful drug screening solution that allows
on-site screening and real-time access to results. When paired with
PatientVu(TM), the drug screening results and complete patient records are
securely accessible from anywhere via the internet.
About NOVX Systems Inc.
NOVX Systems is a leading-edge developer of diagnostic productivity
solutions with an initial focus on on-site drugs of abuse testing. NOVX has
received FDA 510(k) clearance and Health Canada Class III license for the iMDx
System; a testing platform that enables fast, secure and reliable screening
for drugs of abuse and adulterants at the point-of-care. With its electronic
case management software, PatientVu, NOVX has a complete and powerful solution
for on-site screening.
NOVX combines state-of-the-art photonics, innovative chemistry and
customer focused design with a comprehensive data-management interface. The
company has an extensive portfolio of optical, electronic, algorithm and
chemically related patents pending.
For further information:
For further information: Dr. Tino Alavie, President and Chief Executive
Officer, (905) 474-5051 ext 229, email@example.com, novxsystems.com;
Media Contact: Annie Zeni, Argyle Communications, (416) 968-7311 ext 225,